Sana Biotechnology

### Executive Summary Sana Biotechnology raised $789.8 million in a Regulation D private placement, with first sale on 2025-10-12. The filing is an initial Form D, not an amendment, indicating a fresh capital raise in synthetic biology and intracellular mRNA delivery. Backed by Shield Capital and Founders Fund, this is one of the largest private biotech raises in recent years. ### Investor Edge Watch for a potential IPO or SPAC merger within 12-18 months, as the capital raised is sufficient for Phase 2/3 trials. Monitor SEC filings for a Form D amendment (D/A) which would indicate additional capital or terms changes. ### Sector capital positioning This massive raise signals strong institutional appetite for synthetic biology and mRNA delivery platforms, likely accelerating competition in gene editing and cell therapy. The $789.8M amount dwarfs typical early-stage biotech rounds, suggesting a late-stage or crossover round. ### Convergence Signals No direct public signals (patents, contracts, legislation) are evident from the filing data. However, the involvement of Founders Fund and Shield Capital may indicate upcoming clinical trial milestones or platform partnerships. ### Key Takeaways - Sana Biotechnology raised $789.8M in a private placement, one of the largest in synthetic biology. - First sale date 2025-10-12, initial Form D (not an amendment) suggests fresh capital. - Backed by Shield Capital and Founders Fund, indicating strong VC/PE support. ### Risk Indicators & Flags No red flags: initial Form D, no amendments, sector and amount are consistent with late-stage biotech. However, the company is private with no ticker, so liquidity risk exists for investors. ### Verification & References Verify filing at SEC EDGAR using accession number 0001702600-24-20327. Confirm first sale date 2025-10-12 and capital raised $789.8M. Related persons Shield Capital and Founders Fund are listed as officers/directors per SEC rules.